Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) CEO Sells $13,723.85 in Stock

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) CEO Scott Braunstein sold 12,145 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.13, for a total value of $13,723.85. Following the sale, the chief executive officer now owns 298,667 shares of the company’s stock, valued at $337,493.71. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Marinus Pharmaceuticals Trading Down 2.4 %

Shares of MRNS stock traded down $0.03 on Friday, hitting $1.22. 388,097 shares of the stock traded hands, compared to its average volume of 1,261,168. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.93 and a current ratio of 3.07. Marinus Pharmaceuticals, Inc. has a twelve month low of $1.10 and a twelve month high of $11.26. The firm’s 50-day moving average price is $1.36 and its two-hundred day moving average price is $4.64. The stock has a market capitalization of $67.02 million, a PE ratio of -0.46 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, meeting the consensus estimate of ($0.68). The business had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. As a group, analysts anticipate that Marinus Pharmaceuticals, Inc. will post -1.87 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Truist Financial reissued a “buy” rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $13.79.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at $34,000. Values First Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares during the period. Hussman Strategic Advisors Inc. lifted its position in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Marinus Pharmaceuticals during the first quarter worth about $384,000. Finally, Trexquant Investment LP acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at about $553,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.